Research
Hormonal
Hormone therapy increases the risk of stroke regardless of the time since menopause or the age of the woman.
Regardless of when you start hormone therapy, your risk of stroke increases. This risk is independent of your age or how long it has been since menopause. If you are considering hormone therapy, this increased stroke risk must be weighed against the potential benefits for menopausal symptoms and the potential CHD benefits (if starting early).
GoodRefutesHIGH confidence
Hormone therapy increased the risk of stroke (HR, 1.32; 95% CI, 1.12-1.56). Risk did not vary significantly by age or time since menopause.
Why this rating
Consistent finding across combined trials with significant HR.
Source
Postmenopausal Hormone Therapy and Risk of Cardiovascular Disease by Age and Years Since Menopause
Jacques E. Rossouw et al. · JAMA · 2007
DOI 10.1001/jama.297.13.1465
rct · n=27347Cited 1,715×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →